These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 38521213)
21. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407 [TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice. Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Alqahtani F; Alanazi WA; Mahmood HM; Alsanea S; Attia SM Int Immunopharmacol; 2021 Jan; 90():107123. PubMed ID: 33168411 [TBL] [Abstract][Full Text] [Related]
24. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553 [TBL] [Abstract][Full Text] [Related]
25. The Development of BTK Inhibitors: A Five-Year Update. Tasso B; Spallarossa A; Russo E; Brullo C Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993 [TBL] [Abstract][Full Text] [Related]
26. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
27. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. Carnero Contentti E; Correale J Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195 [TBL] [Abstract][Full Text] [Related]
28. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. Garg N; Padron EJ; Rammohan KW; Goodman CF J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458 [TBL] [Abstract][Full Text] [Related]
29. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823 [TBL] [Abstract][Full Text] [Related]
30. A Fast and Clean BTK Inhibitor. Gabizon R; London N J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033 [TBL] [Abstract][Full Text] [Related]
31. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790 [TBL] [Abstract][Full Text] [Related]
32. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Zhang D; Gong H; Meng F Molecules; 2021 Aug; 26(16):. PubMed ID: 34443496 [TBL] [Abstract][Full Text] [Related]
33. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776 [TBL] [Abstract][Full Text] [Related]
34. Bruton's Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia. de Porto AP; Liu Z; de Beer R; Florquin S; Roelofs JJTH; de Boer OJ; den Haan JMM; Hendriks RW; van 't Veer C; van der Poll T; de Vos AF Front Immunol; 2021; 12():723967. PubMed ID: 34552589 [TBL] [Abstract][Full Text] [Related]
35. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives. Das D; Wang J; Hong J Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919 [TBL] [Abstract][Full Text] [Related]
36. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996 [TBL] [Abstract][Full Text] [Related]